Torna all'elenco degli studi
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
CODICE STUDIO
NCT04643002
TIPOLOGIA
Ricaduti
NOME SPONSOR
Sanofi
DESCRIZIONE
Trattamento
Active Comparator: Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 1)
- Isatuximab dose, intravenous (IV) weekly (QW) x 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
- Pomalidomide dose os (PO) daily Day 1 to Day 21.
- Dexamethasone dose PO QW.
Leggi tutto
FARMACI UTILIZZATI
Isatuximab, Belantamab Mafodotin, Pomalidomide, Desametasone